BioNTech (NASDAQ:BNTX) PT Lowered to $122.00 at BMO Capital Markets

BioNTech (NASDAQ:BNTX) had its price objective cut by BMO Capital Markets from $123.00 to $122.00 in a report released on Tuesday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also recently issued reports on BNTX. Canaccord Genuity Group reaffirmed a buy rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research note on Friday, March 22nd. UBS Group cut their target price on shares of BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a research report on Wednesday, March 27th. HC Wainwright restated a buy rating and set a $107.00 price target on shares of BioNTech in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a neutral rating for the company in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has an average rating of Hold and a consensus price target of $118.82.

BioNTech Stock Performance

NASDAQ:BNTX opened at $92.06 on Tuesday. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The company has a market capitalization of $21.89 billion, a P/E ratio of 22.34 and a beta of 0.25. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $90.53 and a two-hundred day moving average price of $95.92.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, research analysts expect that BioNTech will post -1.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently bought and sold shares of the stock. Harding Loevner LP bought a new position in shares of BioNTech in the 4th quarter valued at approximately $410,984,000. Baillie Gifford & Co. boosted its position in shares of BioNTech by 15.5% in the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock valued at $934,612,000 after acquiring an additional 1,152,541 shares during the period. Clearbridge Investments LLC grew its stake in shares of BioNTech by 41.6% in the third quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock worth $52,595,000 after acquiring an additional 142,344 shares during the last quarter. Primecap Management Co. CA boosted its holdings in BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after purchasing an additional 131,490 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its holdings in BioNTech by 43.1% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after purchasing an additional 127,951 shares during the period. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.